<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01029678</url>
  </required_header>
  <id_info>
    <org_study_id>I08011</org_study_id>
    <nct_id>NCT01029678</nct_id>
  </id_info>
  <brief_title>Concomitant Radio-chemotherapy in the Elderly</brief_title>
  <acronym>RACCOSA</acronym>
  <official_title>Phase II Study Evaluating Treatment With Oral Navelbine and Cisplatin Administered Weekly and Concomitant Radiotherapy in Elderly Patients With no Operable NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierre Fabre Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of non small cell lung cancer (NSCLC)&#xD;
      treatment with cisplatin and oral vinorelbine administered weekly associated with concomitant&#xD;
      radiotherapy in elderly patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>during treatment and during the 4 weeks following the end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>6 months after the end of the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>4 weeks after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin IV</intervention_name>
    <description>Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)</description>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36</description>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>66Gy, 33 fractions, 6 week</description>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 70 years&#xD;
&#xD;
          -  Independent patients (based on the score of geriatric frailty: IADL = 0, ADL = 0, no&#xD;
             geriatric syndrome, low comorbidity (comorbidity index of Charlson to 3 or 4),&#xD;
             depression score 0-1)&#xD;
&#xD;
          -  Performance Status (ECOG) ≤ 1&#xD;
&#xD;
          -  Weight loss &lt;10% of usual weight in the last 3 months&#xD;
&#xD;
          -  Life expectancy greater than 12 weeks&#xD;
&#xD;
          -  Hematologic function: neutrophils&gt; 1.5 x 10**9 / l, hemoglobin&gt; 9.5 g / dl, platelets&#xD;
             &gt; 100 x 10**9 / l)&#xD;
&#xD;
          -  Renal function: creatinine clearance ≥ 50 ml / min calculated by the formula of MDRD&#xD;
&#xD;
          -  Normal liver function: bilirubin &lt; Limit of Normal (ULN), SGOT and / or SGPT &lt;2.5 x&#xD;
             UNL&#xD;
&#xD;
          -  Respiratory Function: FEV ≥ 40% predicted, PaO2 ≥ 60 mm Hg, KCO ≥ 60% predicted&#xD;
&#xD;
          -  Patient affiliated to a social security regimen or beneficiary of such regimen&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
        The disease&#xD;
&#xD;
          -  Pathological anatomy: CBP non-small cell (squamous cell carcinoma, adenocarcinoma,&#xD;
             large cell carcinoma, undifferentiated carcinoma) histologically or cytologically&#xD;
             proven&#xD;
&#xD;
          -  Stage IIIAN2 considered inoperable stage IIIB&#xD;
&#xD;
          -  Presence of at least one measurable target&#xD;
&#xD;
          -  Delay at least three weeks between surgery and initiation of treatment&#xD;
&#xD;
          -  No prior treatment with chemotherapy or radiotherapy for lung cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 70 years&#xD;
&#xD;
          -  Performance Status (ECOG) ≥ 2&#xD;
&#xD;
          -  Hematologic function: neutrophils &lt;1.5 x 10**9 / l, hemoglobin &lt;9.5 g / dl, platelets&#xD;
             &lt;100 x 10**9 / l)&#xD;
&#xD;
          -  Renal function: creatinine clearance &lt;50 ml / min calculated by the formula of MDRD&#xD;
&#xD;
          -  Hepatic: bilirubin&gt; Upper Limit of Normal (ULN), SGOT and / or SGPT&gt; 2.5 x ULN&#xD;
&#xD;
          -  Respiratory Function: FEV &lt;40% predicted, KCO &lt;60% predicted, PaO2 &lt;60 mmHg&#xD;
&#xD;
          -  Peripheral neuropathy grade&gt; 1&#xD;
&#xD;
          -  Unstable cardiac pathology requiring treatment (heart failure, angor of effort,&#xD;
             arrhythmia) or previous myocardial infarction older than 12 months&#xD;
&#xD;
          -  Deafness not paired or deafness requiring major achievement of an audiogram-cons may&#xD;
             indicate taking cisplatin&#xD;
&#xD;
          -  Neurological or psychiatric disorders prohibiting the understanding of the test&#xD;
&#xD;
          -  Previous history of cancer except basal cell cancer, carcinoma in situ of the cervix&#xD;
             treated or any other cancer treated with surgery alone or radiotherapy alone&#xD;
             extra-thoracic recurrence-free 5 years&#xD;
&#xD;
          -  Significant malabsorption syndrome or disease affecting the functioning of the&#xD;
             gastrointestinal tract&#xD;
&#xD;
        The disease&#xD;
&#xD;
          -  Pathological anatomy: Bronchioloalveolar carcinoma, neuroendocrine carcinoma, small&#xD;
             cell carcinoma&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Pleural drain&#xD;
&#xD;
          -  Carcinomatous lymphangitis&#xD;
&#xD;
          -  Operable Cancer&#xD;
&#xD;
          -  Previously treated for lung cancer disease: radiotherapy, chemotherapy, hormonal&#xD;
             therapy, endobronchial suctioning older less than eight days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chrystèle LOCHER, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CH Meaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier GAP</name>
      <address>
        <city>GAP</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département de Pathologie Respiratoire du CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Meaux</name>
      <address>
        <city>Meaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>December 9, 2009</study_first_submitted>
  <study_first_submitted_qc>December 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2009</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally advanced lung cancer</keyword>
  <keyword>Elderly patients</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 15, 2018</submitted>
    <returned>February 12, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

